Interview: Compass Pathways CEO Kabir Nath Discusses Commercialisation, ‘Psychological Support’ and Competitive Landscape Post published:January 31, 2024 Post category:Interviews/Pα+
Pα+ Psychedelic Bulletin #154: Public & Industry Respond to DEA’s Renewed DOI and DOC Scheduling Plan; TARA Mind Scores $8m Seed; Updates on State Psychedelics Programs Post published:January 26, 2024 Post category:Psychedelic Bulletin/Pα+
Pα+: Knowledge Gaps in Psychedelic Medicalisation, According to ECNP and Regulators Post published:January 17, 2024 Post category:Analysis/Pα+
Pα+ Psychedelic Bulletin #153: MindMed Scraps Microdosing Program; Eagerly Anticipated Ibogaine Study Publishes; Compass Collaborates with Greenbrook; Gilgamesh’s GM-1020 Readout; and more… Post published:January 12, 2024 Post category:Psychedelic Bulletin/Pα+
Pα+ Psychedelic Patent Analysis (November 2023) Post published:January 5, 2024 Post category:Psychedelic Patent Analysis/Pα+
Pα+ Psychedelic Bulletin #151: Psilocybin for BDII, ACNP Readouts, Methylone for PTSD, and More Psychedelic Drug Dev. News Post published:December 14, 2023 Post category:Psychedelic Bulletin/Pα+
Pα+ Psychedelic Bulletin #150: Drug Development and Research Updates Post published:November 29, 2023 Post category:Psychedelic Bulletin/Pα+
Pα+ Psychedelic Patent Analysis (October 2023) Post published:November 24, 2023 Post category:Psychedelic Patent Analysis/Pα+
Pα+ Mini Interview with Ester Kincová and Steve Rolles: Regulating the Non-Medical Use of Psychedelics Post published:November 20, 2023 Post category:Interviews/Pα+